SEC Filing Summary: Pieris Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on November 4, 2015. The registrant is a Nevada corporation with principal executive offices in Freising-Weihenstephan, Germany. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of non-financial events and does not contain audited financial statements or quarterly results.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely discloses the delivery of industry conference presentations.
Guidance, Outlook, and Management Commentary
Under Item 7.01 (Regulation FD Disclosure), the company attached two industry conference presentations as Exhibits 99.1 and 99.2:
- Exhibit 99.1: Presentation at BIO-Europe 2015.
- Exhibit 99.2: Presentation at PEGs Europe Protein & Antibody Engineering Summit.
The filing explicitly states that the information in these exhibits is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act of 1933 filing, except as expressly set forth by specific reference.
Key Facts for Investor Verification
- Verify the content of the attached conference presentations (Exhibits 99.1 and 99.2) for any forward-looking statements or scientific updates, as the 8-K itself contains no data.
- Note that the company name in the metadata request ("Palvella Therapeutics") differs from the registrant name in the filing ("Pieris Pharmaceuticals, Inc."); this filing pertains to Pieris.
- Confirm that the presentations are not legally incorporated by reference into other SEC filings unless specifically cited elsewhere.